Fig. 4: Impact of pre-transplant MRD on clinical outcomes. | Blood Cancer Journal

Fig. 4: Impact of pre-transplant MRD on clinical outcomes.

From: Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group

Fig. 4

The OS of patients with positive and negative MFC-MRD before transplantation (A), the landmark analysis assessing OS within 1 year and between 1 year and 3 years after diagnosis (B), as well as the EFS (C) and CIR (D). The OS (E), landmark analysis assessing OS (F), EFS (G), and CIR (H) of patients with positive and negative KMT2A-r MRD before transplantation. KMT2A-r MRD cases were evaluated with specific KMT2A fusion genes. OS overall survival, EFS event-free survival, CIR cumulative incidence of relapse, MRD measurable residual disease, MFC-MRD flow cytometry-based MRD. Note: The curve does not show the censored points; the censored data are shown at the bottom along with the risk table.

Back to article page